Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.
You may also be interested in...
Spiriva Positive Cmte. Vote Reflects FDA Advisors’ Comfort With Ambiguous Risk
Boehringer Ingelheim’s tiotropium spray gets strong support at Pulmonary-Allergy Drugs Advisory Committee meeting, with lingering safety concerns dismissed as “statistical weeds.”
Spiriva Safety Data Remains Key Hurdle For Respimat Inhaler
Conflicting findings to be discussed at Boehringer Ingelheim’s Aug. 14 advisory committee review of its tiotropium spray as FDA reviewers offer varying opinions on impact of new trial data.
Forest’s LABA/LAMA Delay Gives GSK A Lengthy Lead On The Market
News that Forest/Almirall’s LABA/LAMA combination will be delayed due to a manufacturing issue means that GlaxoSmithKline’s Anoro Ellipta will continue to dominate the market as the sole fixed-dose combination available in the U.S.